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Abstract 
Parkinson’s disease (PD) is a neurodegenerative 
disorder linked to the accumulation, misfolding, and 
aggregation of the α-synuclein protein in dopaminergic 
neurons of the midbrain, which might ultimately lead to 
the death of these neurons. Until recently, the 
proteasome was believed to be the main pathway for α-
synuclein degradation; however, strong evidence 
emerged that supports the lysosome as another 
mechanism that effectively degrades the protein. The 
two pathways to the lysosome are autophagy and 
endocytosis. More evidence for autophagy as a 
mechanism for α-synuclein degradation is available, 
even though some studies point to the MVB/endocytosis 
pathway a route for membrane bound and extra cellular 
protein degradation. I propose the hypothesis that the 
MVB/endocytosis pathway is a route through which α-
synuclein is targeted to the lysosome. Using S. 
cerevisiae as a model system, I will assess if α-
synuclein accumulates, changes localization, and 
induces cell toxicity in yeasts genetically compromised 
for endocytosis at the pre-ESCRT step: vps27 and 
vps34. The pre-ESCRT gene knockouts will be 
compared with intact endocytosis intact yeast strains, 
while also comparing α-synuclein containing vectors to 
α-synuclein absent vectors. With around four million 
people affected worldwide, finding a cure for PD is a 
worldwide concern and priority.   
 
Background 
 
Our society is affected with a variety of human disorders; 
amongst them are a group of disorders classified as the 
neurodegenerative disorders. These disorders affect the 
brain and are characterized by the death of specific neurons. 
Parkinson’s disease (PD) is a neurodegenerative disorder 
first described in 1817 by James Parkinson. The disorder is 
incurable, and classic symptoms include resting tremors, 
muscular rigidity, bradykinesia, and postural instability (1). 
The importance of studying this disease is apparent when 
looking at the statistics: around four million people worldwide 
are afflicted, and it is expected that by 2040, 
neurodegenerative disorders such as Alzheimer’s disease 
and Huntington disease will surpass cancer as the leading 
cause of death (2). These diseases are caused by the 
accumulation of different proteins. In PD specifically, α-
synuclein is the protein thought to be involved (3). Lewy 
bodies, which are inclusions of α-synuclein, are found in the 
substantia nigra region of the midbrain in PD patients. These 
individuals experience a loss of dopamine neurons in this 
area of the brain (2, 4, 5, 6). The loss of these dopamine-
secreting cells leads to the motor deficiencies seen in the 
patients. PD can occur in two forms: sporadic or familial. 
Initially, the update of 1-Methyl-4-phenyl-4-propionoxy-
piperidine (MPPP), a byproduct of synthetic heroin, caused 
PD-like symptoms in patients (7). Now it is known that the 
misfolding and accumulation of wild-type (WT) α-synuclein 
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leads to the sporadic case of PD. Point mutations in α-
synuclein, on the other hand, cause familial forms of the 
disease. Six genes have been identified in the development 
of familial PD: α-synuclein (1), parkin (8), UCH-L1 (9), DJ-1 
(10), PINK1 (11), and LRRK2 (12). Currently, no cure for PD 
has been found, but some medications to alleviate the 
symptoms are available. Unfortunately, some patients 
eventually become resistant to the medication (2). 
α-Synuclein is a neuronal protein that is found in 
the brain. It is a protein that has been implicated in a variety 
of Neurodegenerative diseases, including PD and AD. The 
presence of a weak transient or residual secondary structure 
in the protein is what may be playing a role in amyloid fibril 
formation, therefore playing a role in its aggregation. Its 
plastic characteristic is mainly due to its C-terminal region, 
which is acidic and always remains unstructured (13). A 
large element of the protein is in its localization in 
presynaptic nerve terminals (14) and its ability to bind to 
phospholipids membranes (15). Recently, data implicates 
that α-synuclein is delivered to the plasma membrane 
through its interactions with the secretory pathway (ER-
Golgi) (16). In yeast models, WT and the other familial 
mutant, E46K, localize in the plasma membrane. The familial 
mutant A30P localizes in the cytoplasm (17). To further 
support α-synuclein’s gain of function characteristics in PD, 
experiments in animal models have shown PD-like 
symptoms with α-synuclein over expression. This was 
demonstrated with wild-type α-synuclein and its familial 
mutants (A30P and A53T) in mice (18), flies (19), and worms 
(20). The past decade has given tremendous insight into the 
PD field, but some questions on the molecular basis of PD 
remain unanswered. Some questions include: if α-synuclein 
is toxic to yeast, what is the causative agent? What is the 
role of oxidative stress in PD pathogenesis? Another major 
question in the field is if α-synuclein accumulation is what 
causes PD. If so, a better understanding of the different 
routes α-synuclein takes to become degraded is essential for 
developing treatments.  
The lysosome as a degradation pathway has been 
less studied than the proteasome. Studies have shown that 
proteasome inhibition leads to α-synuclein inclusion 
formation (21, 22). A knockout mouse model for the 
essential subunit of the 26S proteasome resulted in mice 
with intra-neuronal Lewy-like inclusions and 
neurodegeneration in the nigrostriatal pathway (23). These 
results highlight the proteasome as a key organelle in α-
synuclein degradation. Recently, accumulating evidence 
implicated the lysosome as a means for α-synuclein 
degradation (24). Two pathways to the lysosome exist: 
autophagy and endocytosis. Focus on the lysosome has 
built up due to mounting contradicting evidence that 
demonstrated no changes in levels of α-synuclein with 
proteasome inhibition (21, 25). Cuervo et al. (2004) 
conducted experiments that showed WT α-synuclein is 
internalized and degraded by the lysosome through 
chaperone-mediated autophagy (CMA). The A30P and A53T 
mutants, on the other hand, were not degraded using this 
mechanism (26). Results were confirmed in similar 
experiments with inhibited CMA and macroautophagy that 
resulted in WT α-synuclein accumulation (27). Other 
experiments with autophagy found evidence of the presence 
of α-synuclein in authophagic-like vesicles. Data also 
showed that autophagy inducers, like rapamacyn, increased 
the clearance of α-synuclein in PC12 cell lines (28).  
Although some evidence links α-synuclein 
degradation to the lysosome, like the studies mentioned 
above, these mostly focus on autophagy, one of the two 
 	  
pathways to the lysosome. Little evidence exists that focuses 
on the other pathway to the lysosome for α-synuclein 
degradation: the endocytosis pathway. The endocytosis 
pathway brings in proteins from outside or from the plasma 
membrane into the cell and to the lysosome. Proteins are 
degraded using multivesicular bodies (MVBs), which are 
vesicles that form inside the late endosome. MVBs are 
formed when the endosome membrane invaginates into the 
lumen. The invagination is made possible by the endosomal-
sorting complex required for transport (ESCRT). The ESCRT 
complex helps form MVBs, which then make it possible for 
those membrane-bound proteins to be degraded once the 
endosome and lysosome fuse (29, 30, 31).  Few studies 
focus on the endocytosis/MVB pathway as a mechanism for 
α-synuclein degradation. This is relevant because studies in 
yeast knockouts of key endocytosis genes show α-synuclein 
dependent toxicity (32). Also, data shows that in C. elegans 
endocytosis gene knockouts, there was an accumulation of 
phosphorilated α-synuclein (33). Even though α-synuclein is 
mostly a cytoplasmic protein, small amounts of its 
aggregated form are found outside the cells in PD patients, 
in particular in the blood plasma and cerebrospinal fluid. Lee, 
H. J. et al. (2008) showed that this extra cellular 
accumulated α-synuclein was internalized using the 
endocytosis pathway and eventually degraded by the 
lysosome (34). Therefore, my hypothesis is that the 
MVB/endosome pathway is a route through which α-
synuclein is targeted to the lysosome.  
S. cerevisiae (budding yeast) will be used as a 
model organism for the role of the endocytosis/MVB pathway 
in α-synuclein degradation. This eukaryotic model system is 
effective in the study of different neurodegenerative 
diseases; budding yeast are used in the study of 
Huntington’s disease and PD, among others (16, 17, 32, 35, 
36). The MVB pathway to the lysosome has been conserved 
from yeasts to humans because of its importance (30). It is 
also easy to use these organisms, because their genetic 
code has been decoded, and the entire gene knockout 
library is available. Eleven proteins are involved in the 
ESCRT complex. Five of these eleven yeast genes were 
studied under Alex Ayala’s senior thesis work in our lab (37) 
and the remaining five are currently being studied. The two 
pre-ESCRT proteins, vps34 and vps27, have not been fully 
analyzed, and their role in α-synuclein degradation is 
unknown. vps34 has been found to be required for protein 
and membrane trafficking events such as MVB formation 
(38). vps27 also mediates endosomal protein sorting (39). I 
propose that vps34 and vps27 are required for the 
functioning of this pathway and that the absence of them 
would lead to disruptions in the MVB/endosome pathway 
and accumulation of proteins, including α-synuclein. 
 
Significance 
 
Intellectual Merit: No treatment for the inconvenience and 
hardships caused by neurodegenerative disorders exists 
today. Around four million individuals are affected with PD, 
and out of those, 500,000 to one million are afflicted in North 
America alone. On top of the high number of afflicted 
individuals, the costs of treatment are unapproachable for 
many. Patients nowadays spend more than $200 a month 
for a typical drug treatment regiment (40). The research 
being done will help in understanding the mechanism by 
which α-synuclein is removed from PD patients and 
eventually lead to the development of a cure or information 
that will help in the cure of similar diseases.  
 
Broader Relevance: The broader relevance to this research 
as an undergraduate professor at a liberal arts college can 
be seen through the accomplishments of the undergraduate 
researchers working in my lab. Through lab work, these 
students receive an in-depth, hands on, and focused 
biological learning experience. These students also learn 
key laboratory techniques that can be applied in any field. 
We are training well-prepared undergraduates for diverse 
biological careers in research, medicine and allied health. 
 
Specific Aims 
 
1. Assess if α-synuclein accumulates in yeasts genetically 
compromised for endocytosis at the pre-ESCRT step. 
2. Assess α-synuclein localization in yeasts genetically 
compromised for endocytosis at the pre-ESCRT step. 
3. Assess if α-synuclein induces cellular toxicity in yeasts 
genetically compromised for endocytosis at the pre-
ESCRT step. 
 
Design and Methods 
 
1. Assess if α-synuclein accumulates in yeasts 
genetically compromised for endocytosis at the 
pre-ESCRT step. 
 
Rationale: To evaluate if α-synuclein is accumulating in the 
cells due to the endocytosis pathway being compromised, 
we will evaluate α-synuclein expression in specific gene 
knockouts for proteins at the pre-ESCRT step in yeast. In 
past papers from our lab, Western blots and loss of induction 
assays have been an effective way to show accumulation. 
Western blots will be performed because of their 
effectiveness to code for α-synuclein using the anti-V5 
antibody. Loss of induction assays will confirm Western blot 
results and give α-synuclein degradation comparisons over 
time (36, 37).   
 
Method: Three groups of cells will be examined: the two 
knockout strains for pre-endocytosis/MVB pathway genes 
(vps34 and vps27) and the control with intact endocytosis 
genes (BY4741). Using Western blot and loss of induction 
assays, accumulation of α-synuclein will be examined in 
yeasts genetically compromised for endocytosis and intact 
endocytosis pathway yeast cells.  
1. Yeast Expression: α-synuclein expression 
plasmid vectors will be inserted into the above budding yeast 
strains using the transformation technique described in 
Burke et al. (2000). For selection, yeast cells will be grown 
on media lacking uracil (SC-URA). Plasmid polymerase 
chain reaction (PCR) will confirm α-synuclein expression. 
The pYES2.1 vector will allow for regulation of α-synuclein 
expression because of the presence of the galactose 
inducible promoter (GAL1). V5 and Green fluorescent 
protein (GFP) are also present in vectors. 
2. Development of 5 plasmid constructs: Five 
different plasmids will be inserted to create the five different 
plasmid constructs: Parent plasmid alone (PP), plasmid with 
GFP, wild-type α-synuclein with GFP (WT), A30P mutant α-
synuclein with GFP, and E46K mutant α-synuclein with GFP 
will be the five plasmid constructs for the three different 
groups. Therefore, the parent plasmids, cells with GFP (non-
toxic proteins), and cells with α-synuclein vectors under non-
inducing conditions will serve as controls. 
3. Testing for α-synuclein in Western Blots: The 
cells will be grown in galactose for 24 hours, equal numbers 
of yeast cells expressing GFP, WT, A30P, and E46K for both 
vps knockout strains and BY4741 will be made into cell 
lysates as described in Sharma et al. (2006). Using SeeBlue 
as molecular standard, these proteins will be run in Tris-
glycerine gels, transferred to a PVDF membrane, washed as 
described by Sharma et al. (2006), and blotted for both anti-
V5 and anti-PGK antibodies. The anti-V5 antibody is 38	  
 	  
detecting for the α-synuclein protein. The results seen in the 
anti-V5 blot will give the accumulation results for α-synuclein. 
The anti-PGK blot will be the loading control. Two Western 
blots for each knockout strain and BY4741 will be performed 
to confirm results.  
4. Testing for α-synuclein in Loss of Induction: The 
cells will be grown in galactose for 24 hours as described 
above, and then they will be transferred to glucose media 
and grown for 24 hours. Cell lysates will be prepared as 
described above at 24-hour galactose, 0, 6, 12, and 24 hour 
glucose for each knockout strain and BY4741. The cells will 
be washed and run on the gels as described above. Results 
will demonstrate how well the cells are degrading the α-
synuclein left after the induction media. Two loss of induction 
blots for each knockout strain and BY4741 will be performed 
to confirm results. 
Prediction: In the knockout strains, WT and E46K 
will accumulate and thus show a stronger/thicker band in the 
western blot compared to the mutant strains and GFP 
control. In the loss of induction assay, WT will take longer to 
degrade in the knockout strain compared to the BY4741 
parent control. The familial PD mutant, A30P, will show no 
difference. 
 
2. Assess α-synuclein localization in yeasts 
genetically compromised for endocytosis at the 
pre-ESCRT step. 
 
Rationale: Cell fluorescent microscopy is a valuable way to 
observe protein localization within a cell. Tagging GFP to α-
synuclein has been an effective method in past studies (17, 
36). Although some labs use immunofluorescence to tag for 
α-synuclein, GFP has been characterized as a better method 
(17). Using GFP, WT α-synuclein localizes intensely at the 
plasma membrane (17). The valuable use of GPF is seen by 
its discovery leading to the acquisition of the Nobel Prize in 
Chemistry in 2008. When key endocytosis genes are 
comprised, it will be expected that the localization of α-
synuclein will change. 
 
Method: Both knockout strain and BY4741 cells will be 
grown in galactose media for 24 hours, and the localization 
of the different cell lines described above will be determined 
using a Nikon TE2000-U florescent microscope, and the 
images will be acquired and quantified using Metamorph 4.9 
Imaging Software. The localization will again be visualized at 
48 hours after induction. Detailed methods are described in 
Sharma et al. (2006). A total of 750 cells will be counted with 
each plasmid construct for each time point. The ratio of cells 
displaying specific fluorescence patterns will be calculated 
and graphed for each plasmid construct. Two picture 
acquisition trials for each knockout strain and BY4741 will be 
performed at both time points to confirm results.  
Prediction: In yeast models, WT and the other 
familial mutant, E46K localize in the plasma membrane. The 
familial mutant A30P localizes in the cytoplasm (17). I predict 
that the WT and E46K α-synuclein localization phenotype 
will change. It will differ from the usual BY4741 WT and 
E46K membrane localization as seen in past studies with our 
lab (36). I expect the α-synuclein to form small aggregates 
within the yeast cell as is seen in human PD brains. A30P 
localization will not change. 
 
3. Assess if α-synuclein induces cellular toxicity in 
yeasts genetically compromised for endocytosis at 
the pre-ESCRT step. 
 
Rationale: α-Synuclein is linked to cell death (17). Past labs 
have used growth curves and spotting assays as good 
measures of cellular toxicity in α-synuclein inducing media 
(17, 36). vps28, an important gene in the ESCRT-I complex 
has shown toxicity in WT α-synuclein with growth curves and 
spotting assays (32). Spotting assays will confirm growth 
curve results and together be better analysis of cell toxicity. 
 
Method: The different plasmid constructs and three groups 
described above will be used. Growth curves and spotting 
assays will be performed.  
1. Growth Curves: Growth curves will be created 
with the five plasmid constructs and with a BY4741 PP 
control. Detailed methods described in Sharma et al. (2004). 
Cells will be grown overnight in glucose media and will have 
equal starting concentrations before being placed into 
galactose. The absorbance of the five different cultures will 
be measured and recorded at 0, 3, 6, 12, 18, 24, 36 and 48 
hours using Hitachi U-2000 Spectrophotometer.  The 
absorbance readings will be plotted against time to produce 
a growth curve. Two absorbance readings will be averaged 
for each plasmid construct for each time trial. Finally, three 
different growth curves for each knockout strain and BY4741 
will be performed to confirm results. All three trials will be 
placed into one cumulative growth curve with averaged 
readings. T-tests will be used to measure significant 
differences in the curves. 
2. Spotting: Cells will be grown in glucose and 
counted as described above. Equal concentrations of cells 
for each of the six plasmid constructs will be serially diluted 
(5-fold) into microwell plates. 3ml will be spotted in glucose 
and galactose plates using multi-channel pipettes and grown 
for either 24 hrs or 48 hours. Three glucose and galactose 
plates will be spotted for each trial. There will be three total 
trials done.  
Prediction: I predict that vps27 and vps34 WT and 
E46K plasmid constructs will grow, overall, slower than the 
BY4741 PP control because α-synuclein is causing toxicity 
to the yeast, and endocytosis is compromised. A30P will not 
show any toxicity in the cells. 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication and 
should be cited as such only with the consent of the author. 
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